Wednesday, October 1, 2025

Prothena's partner Bristol fast tracked for BMS-986446 for treatment of Alzheimer's

 

  • Anti-microtubule binding region-tau antibody being investigated as a potential disease-modifying therapy to slow or delay progression of disease

  • Fast Track Designation recognizes the potential of anti-MTBR tau to be an important treatment option for patients with Alzheimer’s disease

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.